Achieve Life Sciences, Inc. (ACHV) |
|
6.64 0.25 (3.91%)
|
05-16 02:16 |
|
Open: |
6.424 |
Pre. Close: |
6.39 |
|
High:
|
6.87 |
Low:
|
6.424 |
|
Volume:
|
51,106 |
Market Cap:
|
63(M) |
|
|
|
|
Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes of cytisinicline for smoking cessation and nicotine addiction in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license agreements with Sopharma AD and University of Bristol. The company is based in Vancouver, Canada. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
6.88 - 6.91 |
6.91 - 6.93 |
|
Low:
|
6.36 - 6.39 |
6.39 - 6.42 |
|
Close:
|
6.59 - 6.64 |
6.64 - 6.68 |
|
Technical analysis |
as of: 2022-05-13 4:36:04 PM |
|
Overall:
|
 |
| Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
| Target: |
Six months: 8.35 One year: 9.46 |
| Support: |
Support1: 5.61 Support2: 4.67 |
| Resistance: |
Resistance1: 7.15 Resistance2: 8.1 |
| Pivot: |
7  |
| Moving Average: |
MA(5): 6.61 MA(20): 7.18
MA(100): 7.44 MA(250): 7.75 |
| MACD: |
MACD(12,26): -0.3 Signal(9): -0.2 |
| Stochastic oscillator: |
%K(14,3): 37.8 %D(3): 42 |
| RSI: |
RSI(14): 41.1  |
| 52-week: |
High: 10.09 Low: 5.61 |
| Average Vol(K): |
3-Month: 92 (K) 10-Days: 59 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ ACHV ] has closed above bottom band by 25.1%. Bollinger Bands are 14.1% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Headline News |
Sat, 14 May 2022
Achieve Life Sciences (NASDAQ:ACHV) Announces Quarterly Earnings Results, Beats Estimates By $0.09 EPS - Defense World
Thu, 12 May 2022
Achieve Life Sciences, Inc. (ACHV) CEO John Bencich on Q1 2022 Results - Earnings Call Transcript - Seeking Alpha
Thu, 12 May 2022
Achieve Life Sciences Tops Q1 EPS by 1c By Investing.com - Investing.com
Thu, 12 May 2022
MEI Pharma and Kyowa Kirin Announce Acceptance of Two Abstracts for Presentation at the European Hematology Association 2022 Hybrid Congress - Yahoo Finance
Wed, 11 May 2022
Notable earnings after Thursday's close - Seeking Alpha
Wed, 27 Apr 2022
ACHV stock gains on late-stage data for smoking cessation agent (NASDAQ:ACHV) - Seeking Alpha
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
9 (M) |
| Shares Float |
8 (M) |
|
% Held by Insiders
|
0.4 (%) |
|
% Held by Institutions
|
29.8 (%) |
|
Shares Short
|
312 (K) |
|
Shares Short P.Month
|
339 (K) |
Stock Financials |
|
EPS
|
-4.08 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
2.97 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
-47.2 |
|
Return on Equity (ttm)
|
-101.5 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
-3.47 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-29 (M) |
|
Levered Free Cash Flow
|
-17 (M) |
Stock Valuations |
|
PE Ratio
|
-1.63 |
|
PEG Ratio
|
-0.2 |
|
Price to Book value
|
2.23 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
-2.14 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
2020-07-30 |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
